Loading...
XBRU
OXUR
Market cap418kUSD
, Last price  
EUR
Name

Oxurion NV

Chart & Performance

D1W1MN
XBRU:OXUR chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
112.36%
Rev. gr., 5y
-45.20%
Revenues
263k
-55.80%
3,243,0001,252,00030,421,0004,213,0006,175,0002,476,00075,083,000112,781,00013,776,00011,198,0007,104,0005,810,0005,320,0003,946,0002,077,9991,128,000595,000263,000
Net income
-19m
L-40.13%
-10,134,000-15,967,00012,095,000-14,070,000-13,942,000-21,637,00030,415,00026,401,000-51,115,000-37,884,000-60,314,00022,788,000-38,474,000-51,827,000-28,012,000-29,158,000-31,685,000-18,969,000
CFO
-10m
L-51.21%
-8,418,000-14,797,00011,957,000-12,098,000-16,842,000-19,564,00027,789,00025,710,000-46,579,000-27,793,000-20,309,00026,295,000-31,116,000-31,100,000-27,097,000-27,155,000-20,016,000-9,765,000

Profile

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
URL
https://www.oxurion.com
IPO date
Jul 07, 2006
Employees
27
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
263
-55.80%
595
-47.25%
Cost of revenue
12,826
23,422
Unusual Expense (Income)
NOPBT
(12,563)
(22,827)
NOPBT Margin
Operating Taxes
3
7
Tax Rate
NOPAT
(12,566)
(22,834)
Net income
(18,969)
-40.13%
(31,685)
8.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,405
BB yield
-0.06%
Debt
Debt current
12,217
3,948
Long-term debt
445
4,068
Deferred revenue
Other long-term liabilities
12
992
Net debt
10,988
4,425
Cash flow
Cash from operating activities
(9,765)
(20,016)
CAPEX
(1,000)
(59)
Cash from investing activities
72
106
Cash from financing activities
7,822
13,643
FCF
(8,394)
(22,229)
Balance
Cash
1,674
3,591
Long term investments
Excess cash
1,661
3,561
Stockholders' equity
(13,436)
(4,833)
Invested Capital
12,596
8,425
ROIC
ROCE
1,495.60%
EV
Common stock shares outstanding
1,652,094
85,020
Price
190.00
-98.95%
Market cap
16,153,768
-97.68%
EV
16,158,193
EBITDA
(12,167)
(22,474)
EV/EBITDA
Interest
1,969
1,370
Interest/NOPBT